Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor

Kazuya Matsumoto, Akira Sawaki, Nobumasa Mizuno, Kazuo Hara, Susumu Hijioka, Yasumasa Niwa, Masahiro Tajika, Hiroki Kawai, Shinya Kondo, Kenji Yamao

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Imatinib used to be the only effective treatment for advanced gastrointestinal stromal tumor. However, early clinical reports have shown that sunitinib has substantial anticancer activity in patients with advanced gastrointestinal stromal tumor after failure of imatinib. Methods: Eighteen Japanese patients with advanced gastrointestinal stromal tumor who were resistant or intolerant to previous treatment with imatinib were entered into this study. These patients were given sunitinib orally, once daily at a 50-mg starting dose, in 6-week cycles with 4 weeks on and 2 weeks off treatment. Tumor response and drug safety were then evaluated. Results: Median time-to-treatment failure was 207 days. Overall, 5.6% (1/18) of patients achieved partial response, 38.9% (7/18) had stable disease and 44.4% (8/18) had progressive disease. The common adverse events were hand-foot syndrome, liver dysfunction, fatigue, anorexia and hypertension. Mild anemia, leukocytopenia and neutropenia were also noted. Nine patients required dose reduction or cessation because of adverse events. Conclusions: This study demonstrates that sunitinib may be an effective agent for advanced gastrointestinal stromal tumor after failure of imatinib in clinical practice.

Original languageEnglish
Article numberhyq164
Pages (from-to)57-62
Number of pages6
JournalJapanese journal of clinical oncology
Volume41
Issue number1
DOIs
Publication statusPublished - 01-01-2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor'. Together they form a unique fingerprint.

  • Cite this

    Matsumoto, K., Sawaki, A., Mizuno, N., Hara, K., Hijioka, S., Niwa, Y., Tajika, M., Kawai, H., Kondo, S., & Yamao, K. (2011). Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor. Japanese journal of clinical oncology, 41(1), 57-62. [hyq164]. https://doi.org/10.1093/jjco/hyq164